Progress Report: Towia Libermann, Ph.D; Alan Rigby, Ph.D
Co-Investigator: Towia Libermann, PhD–Associate Professor, Medicine, Director, Genomics and Proteomics, Beth Israel Deaconess Medical Center, Harvard Medical School, Director, Dana Farber Cancer Institute Cancer Proteomics Core, Harvard Medical School Co-Investigator: Alan Rigby, PhD–Assistant Professor, Medicine, Director, Program in Drug Discovery and Target Validation, Beth Israel Deaconess Medical Center, Harvard Medical. Read More
Progress Report: Karen Knudsen, Ph.D; Adam Dicker, MD, Ph.D
Co-Investigator: Karen Knudsen, PhD–Associate Professor, Department of Cancer Biology and Urology at the Kimmel Cancer Center, Thomas Jefferson University Co-Investigator: Adam Dicker, MD, PhD–Professor, Chairman of Radiation Oncology, Director of Christine Baxter Research Laboratory for Experimental Cancer Therapies, Co-Director Radiation Research and Translational Biology Program at the Kimmel Cancer Center,. Read More
Progress Report: Shelton Earp, MD; Joseph Desimone, Ph.D
Co-Investigator: Shelton Earp, MD– Director and Lineberger Professor, Professor of Medicine and Pharmacology, Lineberger Comprehensive Cancer Center, University of North Carolina-Chapel Hill Co-Investigator: Joseph DeSimone, PhD–Chancellor’s Eminent Professor of Chemistry, University of North Carolina-Chapel Hill, William R. Kenan, Jr. Distinguished Professor of Chemical Engineering, North Carolina State University Application of. Read More
Progress Report: Cory Abate-Shen, Ph.D
Investigator: Cory Abate-Shen, PhD–Professor of Urology and Pathology, Director of Research, Department of Urology, Associate Director, Herbert Irving Comprehensive Cancer Center, Columbia University Identification of Oncogenic Pathways Conserved from Mouse to Man Dr. Abate-Shen’s research goals are to identify new molecules that drive prostate cancer progression. Her approach to this. Read More
PCCTC
PCF-Department of Defense Prostate Cancer Clinical Trials Consortium (PCCTC) As part of its aggressive plan to fund and accelerate research—and to speed the results to patients worldwide—PCF has invested more than $45 million in a consortium of 13 leading cancer centers, featuring some of the world’s most respected prostate cancer clinical. Read More
Progress Reports
As part of the award agreement, investigators are expected to make routine progress reports. Members of PCF’s Science Department regularly meet with the award winners to check in on their research. Please check back for new reports as they will be posted as processed. 2009 Creativity Award Reports Cory Abate-Shen, PhD Shelton Earp,. Read More
10/06/2016
A Labor of Brotherly Love and a Passion for a Cause
Over the past 7 years, the city of Philadelphia has become a renowned leader in immuno-oncology. Philadelphia’s success in this pioneering field, which harnesses patients’ own immune systems to fight cancer, has been a source of inspiration for real estate developer Neal Rodin, who has parlayed his entrepreneurial spirit into. Read More
10/05/2016
A New Generation of Researchers Pioneers Life Saving Solutions
PCF's Young Investigator Program gives recent MDs and PhDs the opportunity to conduct breakthrough research at a critical point in their careers as professional scientists. For these researchers, the first 7 or so years following the conferral of the terminal degree is a precarious and uncertain time. Academic positions are in. Read More
Questions to Ask Before Starting Chemotherapy
Since my PSA is rising again, do we discontinue the androgen deprivation therapy ("hormone therapy")? Why or why not? Are there additional hormone therapy approaches that we should explore? Should I get a bone scan or CT scan to determine if the cancer has spread to my bones? What will. Read More
What Can Go Wrong With the Prostate: Cancer, BPH, and Prostatitis
Prostate cancer isn't the only health issue that can develop with the prostate. Learn about the three most common prostate problems. Read More